Rocket


Overview
Financials
News + Filings
Key Docs
Ownership
Insiders


All
All (ex-4s)
10-K
10-Q
8-K
3,4,5
Proxy
Prospectus
Other
Tags
Inv. presentation
Quarterly results
Clarus Therapeutics Holdings, Inc. Create: Alert

All | News | Filings
Date FiledTypeDescription
03/01/2023 8-K Quarterly results
02/22/2023 8-K Regulation FD Disclosure, Financial Statements and Exhibits  Interactive Data
Docs: "CLARUS THERAPEUTICS, INC., MONTHLY OPERATING REPORT, DATED FEBRUARY 21, 2023"
01/24/2023 8-K Regulation FD Disclosure, Financial Statements and Exhibits  Interactive Data
Docs: "CLARUS THERAPEUTICS, INC., MONTHLY OPERATING REPORT, DATED JANUARY 23, 2023"
11/23/2022 8-K Regulation FD Disclosure, Financial Statements and Exhibits  Interactive Data
Docs: "CLARUS THERAPEUTICS, INC., MONTHLY OPERATING REPORT, DATED NOVEMBER 21, 2022"
10/24/2022 8-K Quarterly results
10/18/2022 8-K Other Events, Financial Statements and Exhibits  Interactive Data
Docs: "PRESS RELEASE OF CLARUS THERAPEUTICS HOLDINGS, INC., DATED OCTOBER 18, 2022."
09/15/2022 8-K Changes in Registrant's Certifying Accountant, Financial Statements and Exhibits  Interactive Data
09/06/2022 8-K Quarterly results
08/26/2022 8-K Quarterly results
08/18/2022 8-K Quarterly results
08/18/2022 8-K Quarterly results
08/09/2022 8-K Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers: Compensatory Arrangements...
06/15/2022 8-K Quarterly results
06/09/2022 8-K Quarterly results
04/27/2022 8-K Entry into a Material Definitive Agreement, Unregistered Sales of Equity Securities, Financial Statements and Exhibits ...
Docs: "Cover Page Interactive Data File (embedded within the Inline XBRL document)",
"Underwriting Agreement",
"Armistice warrant",
"Warrant Agency Agreement between Clarus Therapeutics Holdings, Inc. and Continental Stock Transfer & Trust Co. LLC",
"Form of Pre-Funded",
"Form of Class A warrant"
04/12/2022 8-K Other Events  Interactive Data
Docs: "UNITED STATES SECURITIES AND EXCHANGE COMMISSION"
03/30/2022 8-K Quarterly results
Docs: "UNITED STATES SECURITIES AND EXCHANGE COMMISSION",
"Clarus Therapeutics Reports Fourth Quarter and Full Year 2021 Financial and Operating Results"
02/25/2022 8-K Quarterly results
01/19/2022 8-K Regulation FD Disclosure, Other Events, Financial Statements and Exhibits  Interactive Data
Docs: "Corporate Presentation of Clarus Therapeutics, Inc. (furnished herewith)",
"Corporate Presentation of Clarus Therapeutics, Inc. (furnished herewith)"
12/21/2021 8-K Entry into a Material Definitive Agreement, Creation of a Direct Financial Obligation or an Obligation under an Off-Balance S...
12/07/2021 8-K Entry into a Material Definitive Agreement, Unregistered Sales of Equity Securities, Other Events, Financial Statements and E...
Docs: "Securities Purchase Agreement, among Clarus Therapeutics Holdings, Inc. and each purchaser party thereto",
"Form of Pre-Funded Warrant",
"Form of Common Stock Warrant",
"Registration Rights Agreement, among Clarus Therapeutics Holdings, Inc. and each purchaser party thereto",
"Clarus Therapeutics Announces $15 Million Private Placement",
"Clarus Therapeutics Announces Closing of Approximately $15 Million Private Placement"
11/18/2021 8-K Quarterly results
Docs: "Clarus Therapeutics Reports Third Quarter 2021 Financial and Operating Results"
09/29/2021 8-K Entry into a Material Definitive Agreement, Creation of a Direct Financial Obligation or an Obligation under an Off-Balance S...
Docs: "Providing for Certain Amendments to said Indenture Supplemental Indenture No. 3 This SUPPLEMENTAL INDENTURE No. 3 dated as of September 28, 2021 is between Clarus Therapeutics, Inc., a Delaware corporation with an address at 555 Skokie Boulevard, Suite 340, Northbrook, Illinois 60062 , and U.S. Bank National Association, as trustee and as collateral agent . This Supplemental Indenture No. 3 supplements and amends that certain Indenture dated as of March 12, 2020 among the Issuer, the Trustee and the Collateral Agent, as amended and supplemented by Supplemental Indenture No. 1 dated as of May 27, 2021 and Supplemental Indenture No. 2 dated as of September 9, 2021, in each case, from the Issuer to the Trustee and the Collateral Agent . The Original Indenture and any and all indentures and in..."
09/20/2021 8-K Investor presentation
Docs: "CORPORATE PRESENTATION OF CLARUS THERAPEUTICS HOLDINGS, INC."
09/15/2021 8-K Entry into a Material Definitive Agreement, Completion of Acquisition or Disposition of Assets, Creation of a Direct Financia...
Docs: "SECOND AMENDED AND RESTATED CERTIFICATE OF INCORPORATION OF THE COMPANY",
"AMENDED AND RESTATED BYLAWS OF THE COMPANY",
"REGISTRATION RIGHTS AGREEMENT",
"FORM OF INDEMNIFICATION AGREEMENT (DIRECTORS)",
"FORM OF INDEMNIFICATION AGREEMENT (OFFICERS)",
"Cover Page Interactive Data File (embedded within the Inline XBRL document)",
"RELEASE OF CLAIMS",
"RELEASE OF CLAIMS",
"RELEASE OF CLAIMS",
"FORMS OF AWARD AGREEMENTS UNDER THE 2021 STOCK OPTION AND INCENTIVE PLAN"
08/27/2021 8-K Submission of Matters to a Vote of Security Holders, Other Events, Financial Statements and Exhibits  Interac...
Docs: "Blue Water Acquisition Corp. Announces Stockholder Approval of Business Combination with Clarus Therapeutics, Inc. GREENWICH, Conn., Aug. 27, 2021"
08/11/2021 8-K Other Events, Financial Statements and Exhibits
Docs: "Press Release"
07/30/2021 8-K Other Events, Financial Statements and Exhibits
Docs: "Blue Water Acquisition Corp. Announces Date for Special Meeting of Stockholders to Vote on Transaction With Clarus Therapeutics, Inc."
07/15/2021 8-K Regulation FD Disclosure, Financial Statements and Exhibits
Docs: "CLARUS THERAPEUTICS ANNOUNCES COMPREHENSIVE SETTLEMENT OF PATENT LITIGATION WITH LIPOCINE"
05/25/2021 8-K Regulation FD Disclosure, Financial Statements and Exhibits
Docs: "Clarus Therapeutics And HavaH Therapeutics Announce Licensing Agreement For Product To Treat Androgen-Dependent Inflammatory Breast Disease And Certain Forms Of Breast Cancer Agreement aims to accelerate development of a unique testosterone treatment for inflammatory breast diseases and estrogen-receptor positive breast cancer NORTHBROOK, Ill. and NORTH ADELAIDE, South Australia, May 25, 2021 /PRNewswire/ -- Clarus Therapeutics Inc. , a pharmaceutical company dedicated to providing solutions to unmet medical needs by advancing androgen and metabolic therapies for men and women, and HavaH Therapeutics , an Australia-based biopharmaceutical company developing androgen therapies for inflammatory breast disease and certain forms of breast cancer by using the innate breast-tissue-specific hormo..."
05/19/2021 8-K Regulation FD Disclosure, Financial Statements and Exhibits
Docs: "Investor Presentation, dated May 2021"
04/27/2021 8-K Regulation FD Disclosure, Financial Statements and Exhibits
Docs: "PRESS RELEASE, DATED APRIL [26], 2021",
"Investor Presentation"
04/22/2021 8-K Notice of Delisting or Failure to Satisfy a Continued Listing Rule or Standard; Transfer of Listing, Other Events, Financial ...
Docs: "Blue Water Acquisition Corp. Receives Expected Notice from Nasdaq Regarding Delayed Annual Report , April 22, 2021 – Blue Water Acquisition Corp. announced today that it received a notice from the Listing Qualifications Department of The Nasdaq Stock Market stating that the Company is not in compliance with Nasdaq Listing Rule 5250 because the Company failed to timely file its Annual Report on Form 10-K for the year ended December 31, 2020 with the Securities and Exchange Commission . The Notice has no immediate effect on the listing or trading of the Company’ s securities on the Nasdaq Capital Market. As previously disclosed in the Current Report on Form 8-K filed on April 15, 2021 by the Company, on April 12, 2021, the staff of the Division of Corporation Finance of the SEC issued a sta..."
04/15/2021 8-K Regulation FD Disclosure
  Next >>

Rocket Data Systems, Inc. © 2019 | Contact Us | Data Disclaimer | Terms of Use | Privacy